SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 1996
LabOne, Inc.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-15975 48-0952323
-------------------- ----------- -------------
(State or other jurisdiction (Commission (I. R. S. Employer
of incorporation File Number) Identification No.)
10310 W. 84th Terrace, Lenexa, KS 66214
---------------------------------------- -------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 913-888-1770
Page 1 of 2
Item 5. Other Events
On June 3, 1996, LabOne, Inc., was notified by Epitope, Inc., that the
Food and Drug Administration (FDA) had approved the OraSure(Registered) HIV-1
Western Blot Test. LabOne plans to include the oral fluid confirmation test
in its standard oral fluid testing services, as soon as the confirmatory test
is available for purchase.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
LabOne, Inc.
Date: June 7, 1996 By /s/ Kurt E. Gruenbacher
----------------------------
Kurt E. Gruenbacher
V.P. Finance and Chief
Accounting Officer
Date: June 7, 1996 By /s/ Robert D. Thompson
----------------------------
Robert D. Thompson
Executive V.P. Finance,
CFO and Treasurer
Page 2
